24833864
2014 May 14
Improvements in the medical and pharmacological management of liver transplantation (LT) recipients have led to a better long-term outcome and extension of the indications for this procedure. Liver tumors are relevant to LT; however, the use of LT to treat malignancies remains a debated issue because the high risk of recurrence. In this review we considered LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), liver metastases (LM) and other rare tumors. We reviewed the literature, focusing on the past 10 years. The highly selected Milan criteria of LT for HCC (single nodule
Cholangiocarcinoma; Hemangioendothelioma; Hepatoblastoma; Hepatocellular carcinoma; Liver cancer; Liver metastases; Liver transplantation; Neuroendocrine carcinoma.
